- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.07. | NewcelX Ltd.: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | 1 | GlobeNewswire (USA) | ||
| 15.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | Laidlaw initiates NewcelX stock with buy rating on diabetes therapy | 1 | Investing.com | ||
| 08.07. | NewcelX beruft Diabetes-Forscher Ricordi in den wissenschaftlichen Beirat | 1 | Investing.com Deutsch | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 08.07. | NewcelX appoints diabetes researcher Ricordi to advisory board | 1 | Investing.com | ||
| 08.07. | NewcelX Ltd.: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 08.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | NewcelX Ltd.: NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | 396 | GlobeNewswire (Europe) | ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion... ► Artikel lesen | |
| 30.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | 650 | GlobeNewswire (Europe) | Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq:... ► Artikel lesen | |
| 27.05. | EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission | 2 | Benzinga.com | ||
| 06.05. | NewcelX akquiriert bis zu 3,4 Millionen Dollar | 1 | punkt4.info | ||
| 01.05. | NLS Pharmaceutics GAAP EPS of -$2.16 | 1 | Seeking Alpha | ||
| 30.04. | NewcelX Ltd.: NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | 550 | GlobeNewswire (Europe) | NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term... ► Artikel lesen | |
| 30.04. | EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug | 3 | Benzinga.com | ||
| 30.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,630 | +0,53 % | Short-Squeeze, Übernahme-Poker und Militär-Vertrag - Warum Novavax, Commerzbank und HPQ Silicon jetzt die Märkte elektrisieren könnten! | 3 Aktien - 3 Chancen: Während Novavax dank des Branchenkollegen Moderna und hoher Leerverkaufsquote auf einen möglichen Short-Squeeze hoffen kann, bahnt sich bei der Commerzbank im Milliardenpoker mit... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,160 | -0,88 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,198 | +2,22 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,359 | +1,41 % | NurExone Biologic! Ein Unternehmen von acht weltweit! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,102 | 0,00 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,605 | 0,00 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,340 | 0,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| NOVOCURE | 14,500 | +0,90 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,200 | -0,54 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,110 | +2,64 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| PALISADE BIO | 2,015 | +0,25 % | Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development | Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,845 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer | FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,536 | +3,38 % | Outlook Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| PERSONALIS | 14,815 | +1,20 % | AKTIONÄR-Tipp Personalis: Der Schlüssel für Moderna und Co - bekommt Tempus AI kalte Füße? | Mit positiven Phase-3-Studiendaten eines personalisierten mRNA-Krebsimpfstoffs bei Melanomen haben Moderna und der Forschungspartner Merck & Co in dieser Woche für Schlagzeilen gesorgt. Doch damit das... ► Artikel lesen | |
| OMEROS | 16,750 | +1,21 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen |
NEWCELX LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,16 % bei einem Aktienkurs von 3,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.